XML 61 R45.htm IDEA: XBRL DOCUMENT v3.20.4
Quarterly Financial Information (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Financial Information
The following tables represent our quarterly financial results (in thousands, except per share data):

2020 Calendar Quarter
First
Second2
ThirdFourthAnnual
Revenue$165,105 $165,169 $180,123 $176,783 $687,180 
Income from operations4,365 12,906 37,356 25,876 80,503 
Net income2,987 81,001 25,424 12,908 122,320 
Net income attributable to ApolloMed4,052 7,044 16,713 10,057 37,866 
Earnings per share - basic
attributable to common stock 1
$0.11 $0.20 $0.46 $0.27 $1.04 
Earnings per share - diluted
attributable to common stock1
$0.11 $0.19 $0.45 $0.26 $1.01 
1 Quarterly earnings per share impacts may not add to full-year earnings per share impacts due to the difference in weighted-average common shares for the quarters versus the weighted-average common shares for the year.
2 Includes a pre-tax gain of $99.6 million related to sale of UCI (Note 6).

2019 Calendar Quarter
FirstSecondThirdFourthAnnual
Revenue$95,757 $130,050 $156,060 $178,751 $560,618 
(Loss) income from operations(3,307)14,728 10,066 10,933 32,420 
Net (loss) income(2,450)10,664 10,739 (1,280)17,673 
Net income attributable to ApolloMed140 3,545 3,704 6,727 14,116 
                                                           
Earnings per share - basic
attributable to common stock 1
$0.00 $0.10 $0.11 $0.19 $0.41 
Earnings per share - diluted
attributable to common stock 1
$0.00 $0.09 $0.10 $0.18 $0.39 
1 Quarterly earnings per share calculations may not add to full-year earnings per share calculations due to the difference in weighted-average common shares for the quarters versus the weighted-average common shares for the year.